The global Cell Gene Therapy Manufacturing Market size was USD 7 Billion in 2022 and is expected to register a revenue CAGR of 26% over the forecast period, according to the latest report by Reports and Data.
The desire to cure numerous hereditary illnesses such as cancer, sickle cell anaemia, and the human Immunodeficiency Virus (HIV) is the primary driver of rising demand for gene and cell therapy. These novel medications are being created utilising gene-editing technologies to correct the genetic defects that cause the disease. Cell gene therapy manufacturing has expanded due to the fast improvement of these gene-editing techniques and their promise to heal previously incurable illnesses.
Moreover, pharmaceutical firms' increasing investment in the development of innovative cell and gene therapy is a crucial driver driving market revenue growth. To satisfy unmet medical needs, these companies are focusing on research and development and bringing novel products to market. Governments all over the globe are also offering financial aid for the development of these novel medicines, fueling revenue growth in the cell gene therapy manufacturing market.
Furthermore, an ageing population that is increasingly susceptible to chronic illnesses has produced a strong need for cell and gene therapy. Demand for personalised medication is a significant driver driving market revenue growth since it allows patients to be treated based on their genetic makeup. Individualized treatment is a significant advancement in the medical field that has considerably assisted the growth of the cell gene therapy manufacturing industry.
Additionally, the production of cell and gene therapies has profited from the expanding usage of automation, which has raised productivity and lowered production costs. Large-scale drug production, which was previously impossible, is now feasible because to automation. The improvement of bioreactor design and other manufacturing techniques has led to an increase in the production of cell and gene therapies.
Request a sample Report of Cell Gene Therapy Manufacturing Market @ https://www.reportsanddata.com/download-free-sample/6044
Some Key Highlights from the Report
- The viral vectors segment is predicted to account for the majority of revenue throughout the projected period. Because of their efficacy in gene transfer, viral vectors are frequently utilised in the manufacture of cell gene therapies. These vectors are utilised for both in vivo and ex vivo gene transfer and are used to treat a variety of genetic illnesses. Moreover, viral vectors have been found to have greater gene transfer efficiency and are hence preferable for gene therapy applications. Moreover, the increasing number of viral vector-based gene treatments in clinical trials is boosting revenue growth in the market. Luxturna, a viral vector-based gene therapy for hereditary retinal disorders, obtained FDA clearance in 2017. Additionally, developments in viral vector production methods, such as the creation of suspension culture techniques and reliable producer cell lines, are projected to fuel viral vectors revenue growth. Increasing demand for viral vectors from gene therapy researchers and manufacturers is likely to provide profitable market possibilities.
- In 2022, the oncology segment had the most revenue share in the worldwide cell gene therapy manufacturing market. The rising prevalence of cancer and the necessity for better cancer therapies are driving revenue growth in the oncology market.
- Due to the presence of biotechnology and pharmaceutical firms active in the research and development of cell and gene therapys in the United States, the market in North America is estimated to account for the greatest revenue share during the forecast period. Because of government funding and friendly regulations, the United States has become a centre for the manufacture of cell and gene therapy. The region's high prevalence of ailments such as cancer and genetic disorders is also increasing the need for these therapies. The established healthcare infrastructure and high level of healthcare spending in the area have also created a favourable environment for the evolution of the cell gene therapy manufacturing industry. Additionally, the region's focus on manufacturing creative and unique medications is expected to boost market development in the next years. The National Institutes of Health (NIH), for example, has made major investments in cell and gene therapy research, which has resulted in the development of a variety of novel medicines.
- Some of the prominent players profiled in the global cell gene therapy manufacturing market include Novartis International AG, Kite Pharma, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Celgene Corporation, bluebird bio, Inc., Spark Therapeutics, Inc., Adaptimmune Therapeutics plc, Ziopharm Oncology, Inc., and Sangamo Therapeutics, Inc.
- Novartis International AG announced a strategic partnership with Molecular Partners AG on December 14, 2021, to develop DARPin medicines for the treatment of cancer and other disorders. Novartis will gain access to Molecular Partners' DARPin platform, which is designed to deliver highly specific and potent therapeutics, as a result of this collaboration.
- Bristol-Myers Squibb Corporation acquired MyoKardia, Inc. on November 17, 2020, a biopharmaceutical business focusing on developing tailored therapeutics for the treatment of cardiovascular disorders. The acquisition sought to broaden Bristol-Myers Squibb Company's cardiovascular disease therapy line.
- Kite Pharma, Inc.: On October 1, 2021, the U.S. Food and Drug Administration authorised Kite Pharma, Inc.'s Tecartus, a cell-based gene therapy for the treatment of mantle cell lymphoma (FDA). Tecartus is the first CAR T-cell therapy to be approved by the FDA for the treatment of mantle cell lymphoma. It is meant to target CD19-expressing cancer cells.
- bluebird bio, Inc.: Bluebird bio, Inc. announced FDA clearance for Zynteglo, a gene therapy for the treatment of transfusion-dependent -thalassemia, on August 17, 2022. Zynteglo is intended to implant a functional copy of the -globin gene into a patient's hematopoietic stem cells, allowing normal haemoglobin synthesis.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/6044
For the purpose of this report, Reports and Data has segmented the global cell gene therapy manufacturing market on the basis of Product Type Outlook, Application Outlook, and Regional Outlook:
Product Type Outlook (Revenue, USD Billion; 2022 - 2032)
- Viral Vectors
- Non-Viral Vectors
Application Outlook (Revenue, USD Billion; 2022 - 2032)
- Oncology
- Rare Genetic Diseases
- Cardiovascular Diseases
- Others
Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Request a customized copy of the report @
https://www.reportsanddata.com/request-customization-form/6044
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs
